WaveMan
WaveMan · Company
SLGL · Sol-Gel Technologies Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

SLGL Sol-Gel Technologies (SLGL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001684693
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
12
13F, latest reported quarter

What the filings say about SLGL

Insiders, 180 days
+$4.5M net bought
1 buyer

Sol-Gel Technologies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Sol-Gel Technologies Ltd. insiders bought a net $4.5M of stock across 48 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Opaleye Management Inc.
BUY
2026-09-14 SECtraded 2026-09-11
1,493
$98.5K
+8.1%
Context
  • 47 earlier Form 4 trades (code P or S) here by this insider (47 buys), the last on Sep 10, 2026.
  • +21.5% median (+28.0% mean) 90-day return after 21 previous buys.
  • The trade is 0.3% of the 540,000 shares held after it.
  • No other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $98.5K of SLGL on Sep 11, 2026; 12 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-09-14 SECtraded 2026-09-10
1,631
$108.9K
+8.1%
Context
  • 46 earlier Form 4 trades (code P or S) here by this insider (46 buys), the last on Sep 9, 2026.
  • +22.6% median (+29.2% mean) 90-day return after 22 previous buys.
  • The trade is 0.3% of the 538,507 shares held after it.
  • No other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $108.9K of SLGL on Sep 10, 2026; 12 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-09-09 SEC
3,097
$212.8K
+4.3%
Context
  • 45 earlier Form 4 trades (code P or S) here by this insider (45 buys), the last on Sep 8, 2026.
  • +23.7% median (+30.4% mean) 90-day return after 23 previous buys.
  • The trade is 0.6% of the 536,876 shares held after it.
  • No other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $212.8K of SLGL on Sep 9, 2026; 12 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-09-09 SECtraded 2026-09-08
3,390
$233.0K
+4.3%
Context
  • 43 earlier Form 4 trades (code P or S) here by this insider (43 buys), the last on Sep 4, 2026.
  • +24.9% median (+33.0% mean) 90-day return after 24 previous buys.
  • The trade is 0.6% of the 533,308 shares held after it.
  • No other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $233.0K of SLGL on Sep 8, 2026; 12 funds added in the latest 13F quarter.
Opaleye Management Inc.
BUY
2026-09-09 SECtraded 2026-09-08
471
$32.7K
+4.3%
Context
  • 43 earlier Form 4 trades (code P or S) here by this insider (43 buys), the last on Sep 4, 2026.
  • +24.9% median (+33.0% mean) 90-day return after 24 previous buys.
  • The trade is 0.1% of the 533,779 shares held after it.
  • No other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Opaleye Management Inc. bought about $32.7K of SLGL on Sep 8, 2026; 12 funds added in the latest 13F quarter.
48 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 43 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$4.5M over 180 days
+$3.9M over 90 days · +$4.5M of it by a 10%+ holder
more than 94% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
12 funds bought in last quarter
below 79% of Pharma & Biotech
Revenue
-67.1% year over year
below 84% of Pharma & Biotech
Margin
-161.2% net margin
below 62% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
29.8% of the float short (float per yahoo 2026-10-26) · 3.0 days to cover · settled 2026-09-30
more than 52% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SLGL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+74.5%12M
-23%+33%+89%+146%2025-102025-122026-022026-042026-062026-082026-10 2026-03-24 · Opaleye Management Inc. bought $2.5M2025-12-30 · Opaleye Management Inc. bought $1.5M2026-08-28 · Opaleye Management Inc. bought $1.4M2025-12-31 · Opaleye Management Inc. bought $944.6K2026-08-28 · Opaleye Management Inc. bought $714.0K2025-12-29 · Opaleye Management Inc. bought $361.5K2026-03-24 · Opaleye Management Inc. bought $360.0K2026-08-28 · Opaleye Management Inc. bought $344.1K2026-08-31 · Opaleye Management Inc. bought $341.2K2026-09-08 · Opaleye Management Inc. bought $233.0K2026-09-09 · Opaleye Management Inc. bought $212.8K2025-11-20 · Opaleye Management Inc. bought $207.2K2025-12-01 · Opaleye Management Inc. bought $162.2K2026-09-04 · Opaleye Management Inc. bought $144.9K2026-05-13 · Opaleye Management Inc. bought $129.5K2026-01-22 · Opaleye Management Inc. bought $122.9K2025-12-17 · Opaleye Management Inc. bought $110.4K2026-09-10 · Opaleye Management Inc. bought $108.9K2026-05-12 · Opaleye Management Inc. bought $102.0K2026-07-02 · Opaleye Management Inc. bought $100.8K2026-05-20 · Opaleye Management Inc. bought $100.7K2026-01-02 · Opaleye Management Inc. bought $100.4K2026-09-11 · Opaleye Management Inc. bought $98.5K2025-12-03 · Opaleye Management Inc. bought $95.4K2026-08-12 · Opaleye Management Inc. bought $68.0K2025-12-26 · Opaleye Management Inc. bought $67.8K2026-07-14 · Opaleye Management Inc. bought $67.6K2026-01-23 · Opaleye Management Inc. bought $64.4K2026-09-04 · Opaleye Management Inc. bought $63.8K2026-09-02 · Opaleye Management Inc. bought $62.1K2026-07-13 · Opaleye Management Inc. bought $57.3K2026-09-01 · Opaleye Management Inc. bought $54.4K2025-12-22 · Opaleye Management Inc. bought $41.9K2025-11-26 · Opaleye Management Inc. bought $37.7K2026-09-08 · Opaleye Management Inc. bought $32.7K2026-07-01 · Opaleye Management Inc. bought $22.5K2026-07-08 · Opaleye Management Inc. bought $22.1K2026-02-13 · Opaleye Management Inc. bought $18.3K2025-12-05 · Opaleye Management Inc. bought $17.5K2026-07-10 · Opaleye Management Inc. bought $16.9K2026-08-31 · Opaleye Management Inc. bought $15.0K2025-12-08 · Opaleye Management Inc. bought $11.9K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SLGL: institutional holders (13F)

13F holdings, latest reported quarter
Opaleye Management Inc.
500,000 sh
$37.1M
GREAT POINT PARTNERS LLC
274,363 sh
$20.3M
Phoenix Financial Ltd.
146,147 sh
$10.8M
Trails Edge Capital Partners, LP
139,445 sh
$10.3M
Affinity Asset Advisors, LLC
84,900 sh
$6.3M

Congress trades in SLGL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SLGL planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
5 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 2
0 active
3
Phase 3
0 active
What changed recently
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face
2026-09-19 · Active Not Recruiting → Completed
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $4.5M bought by insiders over 180 days, 12 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SLGL financials

Revenue growth
-67.1%
XBRL, annual
Net margin
-161.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
2.86x
current debt only, 2017-12-31; equity 2025-12-31
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$248.3M
market value at close 2026-10-26 on 2025-12-31 shares, plus current debt only, 2017-12-31, minus cash 2025-12-31
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$19.4M$11.5M$1.6M$3.9M
Operating income-$7.5M-$12.0M-$29.3M-$16.2M
Net income-$6.1M-$10.6M-$27.2M-$14.9M
EPS (diluted)-2.19-3.79-10.01-0.65
Operating cash flow$322.0K-$13.9M-$17.7M-$9.5M
Cash$11.0M$19.5M$7.5M$12.4M
SEC XBRL, fiscal years, as known on 2026-10-28

SLGL Stock Sonar score 5/7 axes

Find similar shapesCompare

SLGL ranks highest on insider conviction (75th percentile) and institutional and government (21st), and lowest on risk and compliance (5th), among Pharma & Biotech peers.

HealthGrowthInsidersInstitutionsRisk
Financial health
7
Inputs
  • Debt to equity2.86x · 7 pct, sector of 352
  • Cash flow to debtneeds four quarters of operating cash flow
Growth
16
Inputs
  • Revenue growth, YoY-67.1% · 16 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
75
Inputs
  • Net Form 4 buying (codes P and S), 180d$4.5M · 93 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
21
Inputs
  • Funds adding, latest quarter12 · 21 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
5
Inputs
  • Short interest, % of float+29.8% · 5 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Profitability, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SLGL filings, in plain words

Are Sol-Gel Technologies insiders buying or selling SLGL?

In the 180 days to 2026-10-28, Sol-Gel Technologies insiders were net buyers, a net $4.5M across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Sol-Gel Technologies insiders were net buyers of SLGL, a net $4.5M across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $4.5M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies